3don MSN
Small differences in cell structures called microtubules determine how well cancer drug performs
A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), ...
New therapies like T-cell engagers and antibody-drug conjugates are showing survival gains in pretreated small cell lung ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
Olvi-Vec shows potential in treating advanced lung cancer, demonstrating tumor shrinkage and disease control in patients unresponsive to platinum-based treatments. The investigational therapy is an ...
EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
What Is Hernexeos, and Why Does It Matter? Hernexeos (zongertinib) is a prescription medicine known as a kinase inhibitor that is used for treating adults with advanced non-small-cell lung cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results